Concepedia

Dan E. Lind

DE

9

Publications

294

Citations

9

H-Index

2019

Active since

Affiliations

University of Gothenburg(Current)

Ghent University

Sahlgrenska University Hospital

Dan E. Lind is an author at University of Gothenburg specializing in medicine, radiation oncology, and tumor biology.

ORCID

Top concepts

Publications per year

2019–2024

9

Publications

9

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of <i>ALK</i> mutation

Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai et al. · The EMBO Journal · 2021 · 62 citations · Full text

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma

Joachim T. Siaw, Niloufar Javanmardi, Jimmy Van den Eynden et al. · Cell Reports · 2020 · 51 citations · Full text

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna Szydzik, Dan E. Lind, Badrul Arefin et al. · Nature Communications · 2021 · 51 citations · Full text

, , +16

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Muhammad Wasi Alam, Marcus Borenäs, Dan E. Lind et al. · Frontiers in Oncology · 2019 · 37 citations · Full text

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

Diana Cervantes-Madrid, Joanna Szydzik, Dan E. Lind et al. · Scientific Reports · 2019 · 27 citations · Full text

Rows per page

1–5 of 9